AbbVie Inc. $ABBV Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC cut its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 231,286 shares of the company’s stock after selling 6,502 shares during the period. AbbVie makes up approximately 0.6% of Yousif Capital Management LLC’s holdings, making the stock its 19th biggest position. Yousif Capital Management LLC’s holdings in AbbVie were worth $53,552,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Trust Co. of Vermont boosted its stake in shares of AbbVie by 7.7% during the 3rd quarter. Trust Co. of Vermont now owns 174,524 shares of the company’s stock worth $40,409,000 after acquiring an additional 12,456 shares in the last quarter. Cliftonlarsonallen Wealth Advisors LLC lifted its holdings in shares of AbbVie by 2.4% during the third quarter. Cliftonlarsonallen Wealth Advisors LLC now owns 25,160 shares of the company’s stock valued at $5,825,000 after purchasing an additional 598 shares during the last quarter. Martel Wealth Advisors Inc acquired a new position in shares of AbbVie in the 3rd quarter valued at $224,000. Farther Finance Advisors LLC boosted its position in shares of AbbVie by 21.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 47,658 shares of the company’s stock valued at $11,035,000 after purchasing an additional 8,558 shares during the period. Finally, Parcion Private Wealth LLC increased its stake in AbbVie by 5.5% in the 3rd quarter. Parcion Private Wealth LLC now owns 16,515 shares of the company’s stock worth $3,824,000 after purchasing an additional 868 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 0.4%

NYSE ABBV opened at $228.74 on Wednesday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14. The company has a market capitalization of $404.28 billion, a PE ratio of 173.29, a price-to-earnings-growth ratio of 1.29 and a beta of 0.36. The firm’s fifty day simple moving average is $226.57 and its 200-day simple moving average is $211.87.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Guggenheim upped their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Scotiabank started coverage on shares of AbbVie in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. UBS Group boosted their target price on shares of AbbVie from $195.00 to $220.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research report on Wednesday, November 5th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $245.84.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.